Beijing Luzhu Biotechnology Co., Ltd. (LUZHU BIOTECH-B) Aktie

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.